Article
Gastroenterology & Hepatology
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Yuki Tanaka, Shun Ishido, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Yuka Hayakawa, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, Namiki Izumi
Summary: The aim of this study was to establish a target value of ALT level during NA treatment as a risk marker for HCC. The results showed that patients with ALT <21 IU/L at 1 year after NA initiation had a lower risk of HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Environmental Sciences
Ming Hui Li, Hui Hui Lu, Qi Qi Chen, Yan Jie Lin, Zhan Zeng, Yao Lu, Lu Zhang, Jian Ping Dong, Wei Yi, Yao Xie
Summary: During antiviral therapy, changes in cytokine levels were observed, with PEG-IFN showing significant decreases in certain cytokines and increases in others compared to ETV. PEG-IFN also had higher rates of HBeAg and HBsAg disappearance compared to ETV, indicating better immune control and functional cure.
BIOMEDICAL AND ENVIRONMENTAL SCIENCES
(2021)
Article
Medicine, General & Internal
Julian Hercun, Theo Heller, Jeffrey S. Glenn, David E. Kleiner, Christopher Koh
Summary: This study evaluates the impact of nucleos(t)ide analogs on the histological appearance of chronic HDV infection and finds that patients on nucleos(t)ide analogs demonstrate a unique membranous staining pattern.
FRONTIERS IN MEDICINE
(2023)
Review
Medicine, General & Internal
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren
Summary: LLV is defined as persistent or intermittent detectable HBV DNA after 48 weeks of antiviral treatment, and even with long-term therapy, some patients still experience LLV; research on the impact of LLV on clinical outcomes is limited, and there are questions regarding the follow-up treatment for these patients.
CHINESE MEDICAL JOURNAL
(2021)
Article
Gastroenterology & Hepatology
Shun Kaneko, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Yuka Hayakawa, Koji Yamashita, Leona Osawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi
Summary: This study investigated the virological characteristics of HBcrAg in CHB patients and the factors associated with HCC risk in HBeAg-negative patients. Results showed that higher levels of HBcrAg in HBeAg-negative patients were associated with cirrhosis and higher HBV DNA levels, and were an independent predictive factor for HCC development in patients receiving NA therapy.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Hui Shi, Ren Ishikawa, Choon Han Heh, Shigeki Sasaki, Yosuke Taniguchi
Summary: MTH1 is an enzyme that hydrolyzes oxidatively damaged nucleobase to prevent its mis-incorporation into genomic DNA. Research on new compounds has revealed the potential of strong inhibitory effects on MTH1 activity and interactions with its active site.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Beatrice Laupeze, Ventzislav Vassilev, Selim Badur
Summary: Chronic hepatitis B is difficult to cure completely due to various barriers. New therapies, particularly immunotherapies, may offer solutions to address these barriers and improve treatment outcomes.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Microbiology
Masaaki Toyama, Koichi Watashi, Masanori Ikeda, Atsuya Yamashita, Mika Okamoto, Kohji Moriishi, Masamichi Muramatsu, Takaji Wakita, Ashoke Sharon, Masanori Baba
Summary: Novel neplanocin A derivatives have shown potency in inhibiting HBV replication in vitro, reducing HBV RNA levels and antigen production, with a mechanism of action different from clinically approved anti-HBV agents.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Virology
Anders Boyd, Lorenza N. C. Dezanet, Karine Lacombe
Summary: Functional cure, defined by the loss of HBsAg, is the ultimate therapeutic goal for individuals infected with HBV, including those with HIV co-infection. Factors such as HBV infection phase, genotypes, and immune response may impact the achievement of functional cure in this population, highlighting the need for novel therapeutics specifically evaluated for HIV-HBV co-infected individuals.
Review
Health Care Sciences & Services
Yi-Chang Liu, Chi-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao
Summary: With the increasing number of allo-HSCT globally and the prevalence of HBV infection, HBV reactivation post transplantation is a significant issue. Antiviral prophylaxis is crucial in reducing HBV replication and mortality, highlighting the importance of identifying high-risk patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Immunology
Shamaila Kausar, Fahad Said Khan, Muhammad Ishaq Mujeeb Ur Rehman, Muhammad Akram, Muhammad Riaz, Ghulam Rasool, Abdul Hamid Khan, Iqra Saleem, Saba Shamim, Arif Malik
Summary: Antiviral drugs are a class of medicines used to treat viral infections, with strategies focusing on targeting the viruses themselves or host cell factors. Viruses can cause various serious diseases in humans, animals, and plants, and the action mechanism of antiviral drugs includes inhibiting viral nucleic acid synthesis and enhancing cell resistance to viruses.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
(2021)
Article
Immunology
Jeong-Hoon Lee, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Summary: This study found that adding pegylated interferon alfa-2a treatment to chronic hepatitis B patients treated with entecavir, followed by sequential HBV vaccination under an intensified schedule, significantly increases the chance of HBsAg seroclearance compared to entecavir alone.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Katherine E. Squires, Lauren Ogilvie, Alina Jucov, Igor Anastasiy, Nelli Ghicavii, Jade Huguet, Rebeca Melara, Martin Constantineau, Abel De La Rosa, Douglas L. Mayers
Summary: ATI-2173 is a potential medication for the treatment of chronic hepatitis B virus (HBV) infection. This study evaluated its safety, pharmacokinetics, and antiviral activity, showing that ATI-2173 has good safety and antiviral activity during treatment, with sustained viral suppression effects after treatment.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Biochemistry & Molecular Biology
Qian Zhang, Xiaoqing Liu, Xicheng Pang, Huimin Wang, Jinjie Du, Hong Ren, Peng Hu
Summary: Hepatitis B surface antigen (HBsAg) seroclearance is an optimal therapeutic endpoint in chronic hepatitis B (CHB) patients. The mechanisms contributing to HBsAg reduction remain unclear. In this study, HBsAg reduction was associated with decreased levels of certain cytokines and changes in adaptive immune cells. With HBsAg reduction, T-cell subsets imbalance was partially corrected, immune activity of T cells was enhanced, and immune exhaustion was alleviated to some extent.
Review
Chemistry, Medicinal
Georgia-Myrto Prifti, Dimitrios Moianos, Erofili Giannakopoulou, Vasiliki Pardali, John E. Tavis, Grigoris Zoidis
Summary: Hepatitis B virus infection has a significant global impact, with limitations in current antiviral drugs. Recent research on the viral replication cycle has led to the development of novel therapeutic approaches, providing hope for achieving a functional cure of the infection in the future.
Article
Virology
Moises Garcia-Serradilla, Cristina Risco, Beatriz Pacheco
Article
Biochemistry & Molecular Biology
Ping Gao, Xiqiang Cheng, Lin Sun, Shu Song, Mar Alvarez, Joanna Luczkowiak, Christophe Pannecouque, Erik De Clercq, Luis Menendez-Arias, Peng Zhan, Xinyong Liu
BIOORGANIC & MEDICINAL CHEMISTRY
(2019)
Article
Chemistry, Medicinal
Pedro A. Sanchez-Murcia, Sonia de Castro, Carlos Garcia-Aparicio, M. Angeles Jimenez, Angela Corona, Enzo Tramontano, Nicolas Sluis-Cremer, Luis Menendez-Arias, Sonsoles Velazquez, Federico Gago, Maria-Jose Camarasa
ACS MEDICINAL CHEMISTRY LETTERS
(2020)
Article
Chemistry, Medicinal
Samara Martin-Alonso, Mar Alvarez, Maria Nevot, Miguel A. Martinez, Luis Menendez-Arias
ACS INFECTIOUS DISEASES
(2020)
Article
Microbiology
Moises A. Arquez, Samara Martin-Alonso, Robert J. Gorelick, Walter A. Scott, Antonio J. Acosta-Hoyos, Luis Menendez-Arias
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Review
Chemistry, Medicinal
Yujie Ren, Yue Ma, Srinivasulu Cherukupalli, John E. Tavis, Luis Menendez-Arias, Xinyong Liu, Peng Zhan
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2020)
Review
Biotechnology & Applied Microbiology
Samara Martin-Alonso, Estrella Frutos-Beltran, Luis Menendez-Arias
Summary: RTs are enzymes that can generate cDNA from RNA, widely used for detecting RNAs and cloning expressed genes. Improved by protein engineering, RTs are key elements in next-generation sequencing techniques and have shown potential for manipulating eukaryotic genomes.
TRENDS IN BIOTECHNOLOGY
(2021)
Article
Virology
Mar Alvarez, Enrique Sapena-Ventura, Joanna Luczkowiak, Samara Martin-Alonso, Luis Menendez-Arias
Summary: This study investigates the impact of HIV RT inhibitors on PPT and highlights nevirapine and doravirine as the most effective among approved NNRTIs. The N348I/T369I mutation has a dominant effect on RNase H cleavage specificity, while beta-sheets 17 and 18, along with the connecting loop, play a crucial role in determining the RNase H cleavage window of HIV RTs.
Editorial Material
Biochemistry & Molecular Biology
Luis Menendez-Arias
Summary: Molnupiravir can be incorporated into viral RNA and used as template for RNA synthesis, leading to error catastrophe in SARS-CoV-2.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Review
Pharmacology & Pharmacy
Luis Menendez-Arias, Rafael Delgado
Summary: Since the first cases of AIDS appeared in 1981, HIV-1 infection has become a global pandemic, but research has led to the approval of over 30 antiretroviral drugs and combination therapies turning HIV-1 infection into a chronic but manageable disease. However, drug toxicity and acquired and transmitted drug resistance remain major threats to therapy success.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Samara Martin-Alonso, Dongwei Kang, Javier Martinez del Rio, Joanna Luczkowiak, Estrella Frutos-Beltran, Lina Zhang, Xiqiang Cheng, Xinyong Liu, Peng Zhan, Luis Menendez-Arias
Summary: In retroviruses, strand displacement DNA-dependent DNA polymerization catalyzed by viral reverse transcriptase (RT) is crucial for synthesizing double-stranded proviral DNA. This study demonstrates that the loss of RNase H activity in HIV-1 RT does not significantly affect strand displacement during DNA template copying but has a major impact on DNA polymerization during reactions with RNA templates. The findings suggest potential applications in transcriptomics technologies and the development of novel antiretroviral agents.
JOURNAL OF MOLECULAR BIOLOGY
(2022)
Review
Virology
Ikbel Hadj Hassine, Manel Ben M'hadheb, Luis Menendez-Arias
Summary: Mutations can lead to the extinction of RNA viruses, and mutagens can be used as a therapeutic strategy to drive viral populations to extinction. There are several drugs, such as ribavirin, favipiravir, and molnupiravir, that exert antiviral effects through lethal mutagenesis. However, concerns about carcinogenic risks and genotoxicity limit their extended use in antiviral therapy.
Article
Biotechnology & Applied Microbiology
Beatriz Pacheco, Alberto Fernandez-Oliva, Moises Garcia-Serradilla, Cristina Risco
Summary: In this study, the antiviral capacity of four repurposed drugs against BUNV infection was tested. Digoxin showed the strongest inhibitory effect on BUNV infection in Vero and HEK293T cells, as it reduced viral protein expression, affected the cell cycle, and altered mitochondrial morphology. The inhibition of the Na+/K+ ATPase by digoxin played a key role in its antiviral activity.
JOURNAL OF GENERAL VIROLOGY
(2023)
Review
Pharmacology & Pharmacy
Chuanfeng Liu, Lide Hu, Guanyu Dong, Ying Zhang, Edeildo Ferreira da Silva-Junior, Xinyong Liu, Luis Menendez- Arias, Peng Zhan
Summary: Influenza is a respiratory infection caused by influenza viruses, resulting in millions of severe cases and deaths each year. The frequent mutations and resistance to antiviral drugs make it necessary to develop efficient drugs against different strains of influenza. This review summarizes strategies for discovering and developing antiviral agents targeting multiple strains of influenza, including drug design based on structure, mechanism, multivalent interaction, and repurposing.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Chemistry, Multidisciplinary
Yue Ma, Estrella Frutos-Beltran, Dongwei Kang, Christophe Pannecouque, Erik De Clercq, Luis Menendez-Arias, Xinyong Liu, Peng Zhan
Summary: This article discusses strategies for discovering antiviral compounds specifically designed to combat drug resistance, including targeting proteins, drug conformation, new binding sites, and host factors as potential therapeutic approaches.
CHEMICAL SOCIETY REVIEWS
(2021)